Hims & Hers : HIMS

All Hims & Hers Articles

52 Articles

Gerelyn Terzo | Mar 9, 2026 at 9:58 AM EDT

Live Nasdaq Composite: Market Turmoil Persists With All Eyes On $100 Oil

This article will be updated throughout the day, so check back often for more daily updates. The markets are starting…

Rich Duprey | Mar 7, 2026 at 10:56 AM EST

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

In a dramatic reversal of fortune, Hims & Hers Health (NYSE:HIMS) has been rescued by the very company that nearly…

Jordan Chussler | Feb 24, 2026 at 9:24 AM EST

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Shares of Hims & Hers Health (NYSE:HIMS) are trading lower this morning after yesterday’s earnings, and the reason is straightforward:…

Trey Thoelcke | Feb 24, 2026 at 6:40 AM EST

Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft…

Rich Duprey | Feb 20, 2026 at 11:51 AM EST

Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Hims & Hers Health (NYSE:HIMS) just made a bold move to take its personalized wellness platform global. The company announced…

Joel South | Feb 16, 2026 at 11:19 AM EST

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff

Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30…

John Seetoo | Feb 11, 2026 at 7:15 AM EST

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created…

Austin Smith | Feb 9, 2026 at 11:59 AM EST

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…

Douglas A. McIntyre | Feb 9, 2026 at 10:39 AM EST

Hims & Hers Falls Apart, Again

Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.…

Rich Duprey | Feb 7, 2026 at 9:03 AM EST

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its…

Lee Jackson | Jan 12, 2026 at 8:07 AM EST

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Pre-Market Stock Futures: The futures are trading lower on Monday morning after a strong finish to the week on Friday,…

William Temple | Dec 30, 2025 at 9:15 AM EST

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty…

Joel South | Nov 3, 2025 at 3:59 PM EST

Live: Hims & Hers Earnings Coverage

Hims & Hers Health (NYSE: HIMS) reports fiscal third-quarter earnings after the close. The telehealth innovator has become one of…

Rich Duprey | Aug 22, 2025 at 12:13 PM EDT

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in…

Rich Duprey | Aug 6, 2025 at 11:35 AM EDT

There Is Only 1 GLP-1 Stock to Buy In 2025

Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic revolutionized the fight against obesity, shifting…

1 2 3 4

Hims & Hers : HIMS

All Hims & Hers Articles

Live Nasdaq Composite: Market Turmoil Persists With All Eyes On $100 Oil

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall

Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Live: Hims & Hers Earnings Coverage

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

There Is Only 1 GLP-1 Stock to Buy In 2025

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Monthly Gold Income of $4.43 Appeals to Retirees; Volatility Decline Threatens The Flow

A $1.8 Million 401(k) and Social Security Coming Up? Drain It Before 70 to Dodge the IRMAA Cliff

The IRS Loophole That Lets You Give Your Kids Unlimited Money Tax-Free (It's Not the $19,000 Gift Limit)

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Hims & Hers : HIMS

All Hims & Hers Articles

Live Nasdaq Composite: Market Turmoil Persists With All Eyes On $100 Oil

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall

Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Live: Hims & Hers Earnings Coverage

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

There Is Only 1 GLP-1 Stock to Buy In 2025

FIDI’s 4.1% Yield Holds Firm as Dollar Weakness Boosts International Dividends

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Monthly Gold Income of $4.43 Appeals to Retirees; Volatility Decline Threatens The Flow

Featured Reads

A $1.8 Million 401(k) and Social Security Coming Up? Drain It Before 70 to Dodge the IRMAA Cliff

The IRS Loophole That Lets You Give Your Kids Unlimited Money Tax-Free (It's Not the $19,000 Gift Limit)